Leading causes of castration-resistant prostate cancer

被引：0
|
作者：
Lu, Mingqian [1 ,2 ,3 ]
Lu, Hongda [4 ,5 ]
Kong, Qingzhi [4 ,5 ]
机构：
[1] Hubei Univ Chinese Med, Clin Med Coll, Wuhan 430061, Hubei Province, Peoples R China
[2] China Three Gorges Univ, Dept Oncol, Yichang 443003, Hubei Province, Peoples R China
[3] Yichang Cent Peoples Hosp, Dept Oncol, Yichang 443003, Hubei Province, Peoples R China
[4] Cent Hosp Wuhan, Dept Oncol, Wuhan 430014, Hubei Province, Peoples R China
[5] Canc Res Inst Wuhan, Wuhan 430014, Hubei Province, Peoples R China
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2015年 / 15卷 / 04期
基金：
湖北省教育厅重点项目;
关键词：
androgen receptor; androgen receptor mutation; androgen receptor splicing; castration-resistant prostate cancer; neuroendocrine; progenitor cells; ANDROGEN RECEPTOR GENE; EPIDERMAL-GROWTH-FACTOR; ANTIANDROGEN WITHDRAWAL SYNDROME; TRANSGENIC MOUSE MODEL; TUMOR-CELL LINES; NEUROENDOCRINE DIFFERENTIATION; STEM-CELLS; SPLICE VARIANTS; FULL-LENGTH; CASODEX BICALUTAMIDE;
D O I：
10.1586/14737140.2015.1007957
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Prostate cancer (PCa) is the second leading cause of cancer-related death in men. Androgen receptor has a key role in the initiation and progression of PCa. Currently, androgen deprivation therapy is the standard treatment for PCa patients due to its effective suppression of androgen receptor signaling. Even though androgen deprivation therapy shows its initial effectiveness on shrinking tumor size, it eventually fails to cure advanced PCa, which is determined by the occurrence of castration-resistance. In this review, we summarize the widely accepted mechanisms that account for castration-resistant PCa and discuss potential therapeutic targets.
引用
收藏
页码：425 / 432
页数：8
相关论文
共 50 条
  • [31] Novel treatments for castration-resistant prostate cancer
    Sternberg, Cora N.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S195 - S199
  • [32] Current State of Castration-Resistant Prostate Cancer
    Petrylak, Daniel P.
    AMERICAN JOURNAL OF MANAGED CARE, 2013, 19 (18): : S358 - S365
  • [33] Cabazitaxel for castration-resistant prostate cancer Reply
    de Bono, Johann Sebastian
    Sartor, Oliver
    LANCET, 2011, 377 (9760): : 122 - 123
  • [34] Satraplatin for the therapy of castration-resistant prostate cancer
    Sonpavde, Guru
    Sternberg, Cora N.
    FUTURE ONCOLOGY, 2009, 5 (07) : 931 - 940
  • [35] Effect of dutasteride on castration-resistant prostate cancer
    Azuma, Takeshi
    Matayoshi, Yukihide
    Sato, Yujiro
    Nagase, Yasuhi
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 8 (01) : 133 - 136
  • [36] PARP inhibition in castration-resistant prostate cancer
    Nappi, Lucia
    Gleave, Martin E.
    FUTURE ONCOLOGY, 2016, 12 (05) : 577 - 580
  • [37] About sorafenib in castration-resistant prostate cancer
    Colloca, G.
    Checcaglini, F.
    Venturino, A.
    ANNALS OF ONCOLOGY, 2008, 19 (10)
  • [38] Darolutamide for treatment of castration-resistant prostate cancer
    Rhea, L. P.
    Mendez-Marti, S.
    Aragon-Ching, J. B.
    DRUGS OF TODAY, 2020, 56 (03) : 185 - 193
  • [39] Managing Nonmetastatic Castration-resistant Prostate Cancer
    Mateo, Joaquin
    Fizazi, Karim
    Gillessen, Silke
    Heidenreich, Axel
    Perez-Lopez, Raquel
    Oyen, Wim J. G.
    Shore, Neal
    Smith, Matthew
    Sweeney, Christopher
    Tombal, Bertrand
    Tomlins, Scott A.
    de Bono, Johann S.
    EUROPEAN UROLOGY, 2019, 75 (02) : 285 - 293
  • [40] BRCA mutation and castration-resistant prostate cancer
    Spirina, L. V.
    ANNALS OF ONCOLOGY, 2018, 29
12345